Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study

Daniele Altomare^{1

2}, Lyduine Collij³, Camilla Caprioglio^{1

2}, Philip Scheltens⁴, Bart N M van Berckel³, Isadora Lopes Alves³, Johannes Berkhof⁵, Yvonne de Gier³, Valentina Garibotto^{6

7}, Christian Moro^{1

2}, Léa Poitrine^{1

2}, Julien Delrieu^{8

9}, Pierre Payoux^{10

11}, Laure Saint-Aubert^{10

12}, José Luis Molinuevo^{13

14}, Oriol Grau-Rivera^{13

15

16}, Juan-Domingo Gispert^{13

15

17}, Carolina Minguillón^{13

15

16}, Karine Fauria^{13

16}, Marta Felez Sanchez¹³, Andreea Rădoi¹³, Alexander Drzezga^{18

19

20}, Frank Jessen²¹, Claus Escher²¹, Philip Zeyen²¹, Agneta Nordberg^{22

23}, Irina Savitcheva²⁴, Vesna Jelic²⁵, Zuzana Walker^{26

27}, Ho-Yun Lee²⁷, Lean Lee²⁶, Jean-François Demonet²⁸, Sonia Plaza Wuthrich²⁸, Rossella Gismondi²⁹, Gill Farrar³⁰, Frederik Barkhof^{3

31}, Andrew W Stephens²⁹, Giovanni B Frisoni^{1

2}; AMYPAD Consortium

Affiliations

¹ Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
² Geneva Memory Center, Geneva University Hospitals, Geneva, Switzerland.
³ Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers (UMC) - Location VUmc, Amsterdam, The Netherlands.
⁴ Alzheimer Center, Department of Neurology, Amsterdam University Medical Centers (UMC) - Location VUmc, Amsterdam, The Netherlands.
⁵ Department of Epidemiology and Data Science, Amsterdam University Medical Centers (UMC) - Location VUmc, Amsterdam, The Netherlands.
⁶ Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
⁷ Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland.
⁸ Gérontopôle, Department of Geriatrics, Toulouse University Hospital, Toulouse, France.
⁹ Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier, Toulouse, France.
¹⁰ Department of Nuclear Medicine, Toulouse University Hospital, Toulouse, France.
¹¹ Toulouse NeuroImaging Center (ToNIC), Inserm, Université Paul Sabatier, Toulouse, France.
¹² Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France.
¹³ Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
¹⁴ H. Lundbeck A/S, Copenhagen, Denmark.
¹⁵ Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
¹⁶ Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
¹⁷ Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spain.
¹⁸ Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
¹⁹ German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany.
²⁰ Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany.
²¹ Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
²² Department of Neurobiology, Care Sciences and Society, Center of Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
²³ Theme Aging, Karolinska University Hospital, Stockholm, Sweden.
²⁴ Medical Radiation Physics and Nuclear Medicine, Section for Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
²⁵ Cognitive Disorders Clinic, Theme Inflammation and Aging, Karolinska University Hospital-Huddinge, Stockholm, Sweden.
²⁶ Division of Psychiatry, University College London, London, UK.
²⁷ St. Margaret's Hospital, Essex Partnership University NHS Foundation Trust, Essex, UK.
²⁸ Leenaards Memory Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
²⁹ Life Molecular Imaging, Berlin, Germany.
³⁰ GE Healthcare, Amersham, UK.
³¹ Institutes of Neurology and Healthcare Engineering, UCL, London, UK.

PMID: 35715930
DOI: 10.1002/alz.12696

Randomized Controlled Trial

Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study

Daniele Altomare et al. Alzheimers Dement. 2023 Mar.

. 2023 Mar;19(3):844-856.

doi: 10.1002/alz.12696. Epub 2022 Jun 17.

Authors

Affiliations

¹ Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
² Geneva Memory Center, Geneva University Hospitals, Geneva, Switzerland.
³ Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers (UMC) - Location VUmc, Amsterdam, The Netherlands.
⁴ Alzheimer Center, Department of Neurology, Amsterdam University Medical Centers (UMC) - Location VUmc, Amsterdam, The Netherlands.
⁵ Department of Epidemiology and Data Science, Amsterdam University Medical Centers (UMC) - Location VUmc, Amsterdam, The Netherlands.
⁶ Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
⁷ Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland.
⁸ Gérontopôle, Department of Geriatrics, Toulouse University Hospital, Toulouse, France.
⁹ Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier, Toulouse, France.
¹⁰ Department of Nuclear Medicine, Toulouse University Hospital, Toulouse, France.
¹¹ Toulouse NeuroImaging Center (ToNIC), Inserm, Université Paul Sabatier, Toulouse, France.
¹² Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, Inserm, Université Paul Sabatier, Toulouse, France.
¹³ Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
¹⁴ H. Lundbeck A/S, Copenhagen, Denmark.
¹⁵ Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
¹⁶ Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
¹⁷ Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spain.
¹⁸ Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
¹⁹ German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany.
²⁰ Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany.
²¹ Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
²² Department of Neurobiology, Care Sciences and Society, Center of Alzheimer Research, Karolinska Institutet, Stockholm, Sweden.
²³ Theme Aging, Karolinska University Hospital, Stockholm, Sweden.
²⁴ Medical Radiation Physics and Nuclear Medicine, Section for Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
²⁵ Cognitive Disorders Clinic, Theme Inflammation and Aging, Karolinska University Hospital-Huddinge, Stockholm, Sweden.
²⁶ Division of Psychiatry, University College London, London, UK.
²⁷ St. Margaret's Hospital, Essex Partnership University NHS Foundation Trust, Essex, UK.
²⁸ Leenaards Memory Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
²⁹ Life Molecular Imaging, Berlin, Germany.
³⁰ GE Healthcare, Amersham, UK.
³¹ Institutes of Neurology and Healthcare Engineering, UCL, London, UK.

PMID: 35715930
DOI: 10.1002/alz.12696

Abstract

Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort.

Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.

Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.

Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.

Keywords: Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline.

PubMed Disclaimer

References

REFERENCES

1. Serrano‐Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189‐a006189. https://doi.org/10.1101/cshperspect.a006189
1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound‐B. Ann Neurol. 2004;55(3):306‐319. https://doi.org/10.1002/ana.20009
1. Grundman M, Pontecorvo MJ, Salloway SP, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4‐15. https://doi.org/10.1097/WAD.0b013e318279d02a
1. Boccardi M, Altomare D, Ferrari C, et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]‐Florbetapir (INDIA‐FBP) Study. JAMA Neurol. 2016;73(12):1417‐1424. https://doi.org/10.1001/jamaneurol.2016.3751
1. Zwan MD, Bouwman FH, Konijnenberg E, et al. Diagnostic impact of [18F]flutemetamol PET in early‐onset dementia. Alzheimer's Res Ther. 2017;9(1):2. https://doi.org/10.1186/s13195‐016‐0228‐4

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

115952/The AMYPAD project is funded by the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU)

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study

Affiliations

Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study

Authors

Affiliations

Abstract

References

REFERENCES

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous